Compare · MDLN vs TNDM
MDLN vs TNDM
Side-by-side comparison of Medline Inc. (MDLN) and Tandem Diabetes Care Inc. (TNDM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and TNDM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 41.8x TNDM ($1.15B).
- Over the past year, MDLN is down 11.8% and TNDM is up 9.7% - TNDM leads by 21.5 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 4 for TNDM).
- Both have 25 recent analyst ratings on file.
- Company
- Medline Inc.
- Tandem Diabetes Care Inc.
- Price
- $35.95-1.74%
- $16.24-1.55%
- Market cap
- $48.08B
- $1.15B
- 1M return
- +11.97%
- -5.72%
- 1Y return
- -11.77%
- +9.73%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2013
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 25
Tandem Diabetes Care Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest TNDM
- Barclays initiated coverage on Tandem Diabetes Care with a new price target
- Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
- Citigroup reiterated coverage on Tandem Diabetes Care with a new price target
- Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
- William Blair initiated coverage on Tandem Diabetes Care
- EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 4,120 shares and covered exercise/tax liability with 1,479 shares, increasing direct ownership by 5% to 52,040 units (SEC Form 4) to satisfy withholding tax
- PRESIDENT & CEO Sheridan John F converted options into 15,916 shares and covered exercise/tax liability with 8,099 shares, increasing direct ownership by 5% to 160,260 units (SEC Form 4) (for withholding tax)
- EVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 3,014 shares and covered exercise/tax liability with 1,618 shares (SEC Form 4) to satisfy withholding tax
- EVP & Chief Admin. Officer Morrison Susan converted options into 2,827 shares and covered exercise/tax liability with 809 shares, increasing direct ownership by 4% to 52,788 units (SEC Form 4) (tax withholding)
- EVP & Chief Operating Officer Kyrillos Jean-Claude converted options into 1,010 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 2% to 30,290 units (SEC Form 4) (for withholding tax)